Dr. Jack Leahy, endocrinologist and general internist, Dr. Doron Schneider, weigh different initial treatment options presented by leading endocrinologists Silvio Inzucchi, MD, Alan J. Garber, MD and Laurence Kennedy, MD
- Posted May 29, 2013 by John L. Leahy, MD
The Good, The Bad, and the Ugly Part II: Why I’m not a Fan of the ADA/EASD’s 2012 Position StatementPosted June 6, 2012 by John L. Leahy, MD
- Posted May 30, 2012 by John L. Leahy, MDThe highly awaited ADA/EASD statement on management of type 2 diabetes was published online April 19th, 2012.1 I feel like a curmudgeon,but as a general statement, I’m not a fan. In fact, I’m worried that at best it will have little impact, and at worst could be harmful.
- Posted March 8, 2012 by Irl B. Hirsch, MDPrimary care physicians are expected to be experts on dozens of different disease states despite the fact that each medical problem continues to evolve, with new understanding of the disease itself and its treatments. Frankly, I see this as a near impossible task since as an endocrinologist I can barely keep up with diabetes (in reality I can’t).
- Posted September 21, 2011 by Sonal Singh, MD, MPHSeveral guidelines emphasize the need to use existing therapeutic options to help patients and providers achieve various treatment goals, including target glycated hemoglobin levels to improve microvascular outcomes among patients with type 2 diabetes. 1 Blood pressure medications and lipid lowering therapy and prophylactic aspirin therapy are recommended to improve cardiovascular outcomes. Influenza and pneumococcal vaccination strategies are recommended to reduce the risk of subsequent infections.
- Posted April 7, 2011 by Kim C. Dixon, MD
Fatty liver disease is the most common cause of chronic liver disease in North America and is becoming one of the top reasons for liver transplantation. Fatty liver causes inflammation that can lead to fibrosis, cirrhosis, and hepatocellular carcinoma. The physiologic relationship between type 2 diabetes mellitus and fatty liver disease is complex and multifactorial.
- Posted October 15, 2010 by Christopher J. Rhodes, PhD
Evidence that protecting pancreatic beta cells from chronic overstimulation to maintain glucose homeostasis has led to the concept of “beta cell rest” to preserve or restore beta cell function by temporarily inhibiting insulin secretion. Under normal circumstances this is unnecessary, but in obesity-linked glucose-intolerance and type 2 diabetic conditions beta cells could do with a break.